



PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



Vanda Pharmaceuticals Inc. Rank 46 of 446



The relative strengths and weaknesses of Vanda Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Vanda Pharmaceuticals Inc. is the variable Intangible Assets, reducing the Economic Capital Ratio by 2.4% points.

The company's Economic Capital Ratio, given in the ranking table, is 246%, being 203% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	519,292
Cost of Goods Sold	0
Intangible Assets	18,565
Liabilities, Current	91,436
Liabilities, Non-Current	15,613
Other Assets	93,817
Other Compr. Net Income	-1,018
Other Expenses	30,823
Other Liabilities	0
Other Net Income	0
Other Revenues	259,353
Property and Equipment	2,573
Research and Development	85,770
Selling, General and Administrative Expense	136,485

Output Variable	Value in 1000 USD
Assets	634,247
Liabilities	107,049
Expenses	253,078
Revenues	259,353
Stockholders Equity	527,198
Net Income	6,275
Comprehensive Net Income	5,766
Economic Capital Ratio	246%

